- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Allergy
Volume 2011 (2011), Article ID 547389, 2 pages
Lability of IgE Levels Early in Life
1Laboratoire d'Immunologie Faculté de Médecine, 10 Boulevard Tonnellé, 37032 Tours Cedex, France
2Pilot Center for Therapeutic Antibody Monitoring, CHRU de Tours, France
3Université François-Rabelais de Tours, France
4CNRS, UMR6239, France
5Faculté de Médecine d'Abidjan, Cote D'Ivoire
6Laboratories of Pharmacology, CHRU de Tours, France
7Pediatric Department, CHRU de Tours, France
8INSERM, U921, France
Received 21 February 2011; Accepted 28 April 2011
Academic Editor: Robert A. Wood
Copyright © 2011 Koffi N'guessan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We report a case of a very fast and intriguing decrease in IgE concentrations after exclusion from the diet of any CM lysate in an unusual clinical presentation of cow's milk allergy in an infant. Analysis of IgE kinetics after allergen elimination suggests rapid cessation of IgE biosynthesis and a short IgE half-life.
An unusual clinical presentation of cow's milk allergy (CMA) in an infant gave us the opportunity to observe a very fast and intriguing decrease of IgE concentrations after allergen withdrawal, raising new questions about IgE production and metabolism in newborns and infants.
2. Case Report
A 17-day-old neonate, born to atopic parents at full term, was hospitalized in the children hospital of Tours (France) for poor feeding and increasing diarrhoea for 4 days, associated with a severe metabolic acidosis, after a symptom-free interval of 2 weeks. The diarrhoea ceased soon after admission. Erythema and a pustular rash of the face as well as a “gloves and socks-” type skin rash were noted at 18 days of age, leading to the finding of very high concentrations of total IgE (1298 kIU/L) and IgE specific to cow’s milk (CM) (83 kAU/L, Phadia) (Figure 1). First-stage formula milk had been introduced on day 11 in addition to breastfeeding according to the mother, although it is possible that this had been given since birth. Although the clinical presentation was very unusual and severe [1, 2], the diagnosis of CMA was confirmed by a rapid regression of all symptoms after withdrawal of CM proteins. Seven days later, total IgE fell to 121 kIU/L and specific IgE to 1.44 kAU/L, and total IgE returned to within the normal range (10.5 kIU/L) (Figure 1) five days later.
The IgE detected in the newborn had been self-produced since IgE did not cross the placenta and his mother had no CM-specific IgE (not shown). This IgE immune response thus probably reflected a rapid maturation of IgE+ B cells into plasmablasts, as recently evidenced in mice . No less spectacular was the 100-fold decrease in IgE concentrations 12 days later (Figure 1), following exclusion of any CM lysate from the diet. High levels of both specific and total IgE are regularly observed in infant cow’s milk allergy  and are reminiscent of experimental models where their coexistence reflects a genetic (atopic) background . However, their parallel evolution, and the fact that they both appeared to be strictly antigen dependent, could also suggest that the IgE measured in the “total” assay is mostly directed against CM.
Pharmacokinetic modelling techniques were used to describe the elimination kinetics of total IgE in this infant. The kinetics model was , where is the IgE concentration over time (kIU/L), is the estimated IgE concentration just after CM withdrawal, (day−1) is the first-order elimination constant, and t (day) is time. The parameter was estimated using log-linear regression. The elimination half-life () was calculated as and was 1.7 days in this infant. The combined kinetics of IgE and omalizumab, an anti-IgE humanized monoclonal antibody, were previously described in adults using PK-PD modelling . The parameters describing the interindividual distribution of IgE elimination kinetics in this study were used to estimate the confidence interval containing 90% of values (), which was (1.5–3.8) days. Although low, the of IgE of our infant was within this and thus has to be considered as “normal.” However, to calculate this elimination kinetics, it was postulated that IgE production ceased after CM withdrawal, which is not necessarily the case. It is therefore possible that the true IgE of this patient may be shorter than 1.7 days.
Nevertheless, our findings suggest that the IgE production stopped rapidly—if not immediately—after allergen elimination, suggesting that a very limited IgE plasmablast life span combined with the very short IgE half-life. Whether this hypothetical IgE plasmablast short life span is restricted to IgE or whether it is due a more general immaturity of lymphoid niches in the newborn, as suggested in murine models , warrants further investigations in a cohort of CM allergic newborns.
- L. Y. Siu, K. Tse, and Y. S. Lui, “Severe cow's milk protein allergy in a Chinese neonate,” Hong Kong Medical Journal, vol. 7, no. 4, pp. 442–444, 2001.
- C. Rizk, L. Valdes, H. O. de Baulny, J. M. Saudubray, and C. Olivier, “Severe lactic acidosis disease disclosing milk-protein intolerance to cows' milk,” Archives of Pediatrics, vol. 6, no. 4, pp. 427–429, 1999.
- A. Erazo, N. Kutchukhidze, M. Leung et al., “Unique maturation program of the IgE response in vivo,” Immunity, vol. 26, no. 2, pp. 191–203, 2007.
- A. Dias, A. Santos, and J. A. Pinheiro, “Persistence of cow's milk allergy beyond two years of age,” Allergologia et Immunopathologia, vol. 38, no. 1, pp. 8–12, 2010.
- J. Wyczółkowska, T. Michoń, T. Brzezińska-Błaszczyk, and C. Maśliński, “The relationship between specific IgE antibody and non-specific IgE in anaphylactic sensitization of mice and rats,” Archivum Immunologiae et Therapia Experimentalis, vol. 30, pp. 17–23, 1982.
- N. Hayashi, Y. Tsukamoto, W. M. Sallas, and P. J. Lowe, “A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab,” British Journal of Clinical Pharmacology, vol. 63, no. 5, pp. 548–561, 2007.
- E. Belnoue, M. Pihlgren, T. L. McGaha et al., “APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells,” Blood, vol. 111, no. 5, pp. 2755–2764, 2008.